Court Rules ‘Pay-To-Delay’ Deal Anti-Competitive
A federal appeals court agrees with the Federal Trade Commission that a 2010 deal between Endo International and Impax Laboratories to delay a generic version of Endo’s painkiller for three years in exchange for $112 million was anti-competitive. And drug makers try to prepare for the next viral pandemic.